BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol 2020;13:1756284820941179. [PMID: 32922513 DOI: 10.1177/1756284820941179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Jiang L, Han W, Bai X, Ruan G, Guo M, Zhou R, Liang H, Yang H, Qian J. Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis. Front Immunol 2021;12:742080. [PMID: 34992592 DOI: 10.3389/fimmu.2021.742080] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
3 Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33615953 DOI: 10.1080/14737167.2021.1880324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]